$JVSA
JVSPAC Acquisition Corp.

2023 Q4 Form 10-K Financial Statement

#000121390024028695 Filed on April 01, 2024

View on sec.gov

Income Statement

Concept 2023 Q4 2023 2022 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $26.57K $76.83K $600.00
YoY Change 4328.33% 3392.27%
Operating Profit
YoY Change
Interest Expense $100.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$26.57K -$76.83K -$600.00
YoY Change 4328.33% 3392.27%
Income Tax
% Of Pretax Income
Net Earnings -$26.57K -$76.83K -$600.00
YoY Change 4328.33% 3329.78%
Net Earnings / Revenue
Basic Earnings Per Share -$0.06
Diluted Earnings Per Share $0.00 -$0.06 $0.00
COMMON SHARES
Basic Shares Outstanding 1.250M shares
Diluted Shares Outstanding 1.250M shares

Balance Sheet

Concept 2023 Q4 2023 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $394.4K $394.4K
YoY Change 66.19%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.650K $394.4K
YoY Change 66.19%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $386.7K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $7.650K $394.4K
Total Long-Term Assets $386.7K $0.00
Total Assets $394.4K $394.4K $237.3K
YoY Change 66.18% 66.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.312K $5.310K $11.00K
YoY Change -51.71% -51.73%
Accrued Expenses $200.0K $200.0K $115.8K
YoY Change 72.75% 72.71%
Deferred Revenue
YoY Change
Short-Term Debt $286.4K $286.4K
YoY Change 118.62%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $491.7K $491.7K $257.8K
YoY Change 90.72% 90.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $491.7K $491.7K $257.8K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $491.7K $491.7K
YoY Change 90.73%
SHAREHOLDERS EQUITY
Retained Earnings -$122.3K -$45.50K
YoY Change 168.87%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$97.32K -$97.32K -$20.50K
YoY Change
Total Liabilities & Shareholders Equity $394.4K $394.4K $237.3K
YoY Change 66.18% 66.19%

Cashflow Statement

Concept 2023 Q4 2023 2022 Q4
OPERATING ACTIVITIES
Net Income -$26.57K -$76.83K -$600.00
YoY Change 4328.33% 3329.78%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities $0.00 $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities 0.000 0.000
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash 0.000 $0.00 0.000
YoY Change
FREE CASH FLOW
Cash From Operating Activities $0.00 $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-41922
CY2023 dei Entity Registrant Name
EntityRegistrantName
JVSPAC ACQUISITION CORP.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
D8
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
1 Electric Street
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Wan Chai
CY2023 dei Entity Address Country
EntityAddressCountry
HK
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
N/A
CY2023 dei City Area Code
CityAreaCode
(+852)
CY2023 dei Local Phone Number
LocalPhoneNumber
9258 9728
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 dei Entity Public Float
EntityPublicFloat
0 usd
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 dei Auditor Name
AuditorName
Marcum Asia CPAs LLP
CY2023 dei Auditor Location
AuditorLocation
New York, NY
CY2023 dei Auditor Firm
AuditorFirmId
5395
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7650 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5000 usd
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
386725 usd
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
232313 usd
CY2023Q4 us-gaap Assets
Assets
394375 usd
CY2022Q4 us-gaap Assets
Assets
237313 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5312 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
200000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
115773 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
491697 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
257808 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122322 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45495 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-97322 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-20495 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
394375 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
237313 usd
CY2023 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
76827 usd
CY2022 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2240 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-76827 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-2240 usd
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1250000 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1250000 shares
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-20495 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-76827 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-97322 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-2240 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-76827 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-2240 usd
CY2023 us-gaap Other Noncash Expense
OtherNoncashExpense
76827 usd
CY2022 us-gaap Other Noncash Expense
OtherNoncashExpense
2240 usd
CY2023 jvsa Accrued Offering Costs Paid Under The Promissory Noterelated Party
AccruedOfferingCostsPaidUnderThePromissoryNoterelatedParty
25690 usd
CY2023 jvsa Deferred Offering Costs Paid By Sponsor Under The Promissory Noterelated Party
DeferredOfferingCostsPaidBySponsorUnderThePromissoryNoterelatedParty
70185 usd
CY2022 jvsa Deferred Offering Costs Paid By Sponsor Under The Promissory Noterelated Party
DeferredOfferingCostsPaidBySponsorUnderThePromissoryNoterelatedParty
5000 usd
CY2023 jvsa Deferred Offering Costs Included In The Accrued Offering Costs And Expenses
DeferredOfferingCostsIncludedInTheAccruedOfferingCostsAndExpenses
84227 usd
CY2023 jvsa Prepaid Expense Paid By Sponsor Under The Promissory Noterelated Party
PrepaidExpensePaidBySponsorUnderThePromissoryNoterelatedParty
2650 usd
CY2023 us-gaap Sale Leaseback Transaction Gross Proceeds Financing Activities
SaleLeasebackTransactionGrossProceedsFinancingActivities
2400000 usd
CY2023 us-gaap Investment Company Total Return Market Value
InvestmentCompanyTotalReturnMarketValue
0.80 pure
CY2023Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
1 pure
CY2023 us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
0.2
CY2023Q4 us-gaap Shares Issued
SharesIssued
5000000 shares
CY2023 us-gaap Interest Expense
InterestExpense
100000 usd
CY2023Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
386725 usd
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
232313 usd
CY2023 jvsa Private Placement Abstract
PrivatePlacementAbstract
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 — Private Placement</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company<span style="font-family: Times New Roman, Times, Serif">’</span>s Sponsor has committed to purchase an aggregate of 232,500 units (or 240,000 units if the over-allotment option is exercised in full) at a price of $10.00 per unit for an aggregate purchase price of $2,325,000 (or $2,400,000 if the over-allotment option is exercised in full). Each Private Placement Unit will be identical to the units sold in the Proposed Public Offering, except as described below. The Private Placement Units will be sold in a private placement that will close simultaneously with the closing of the Proposed Public Offering, including the over-allotment option, as applicable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Simultaneously with the consummation of the IPO and the sale of the Units, the Company consummated the Private Placement of 240,000 units to the Sponsor, as disclosed in Note 8.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Founder Shares, private placement shares or private placement rights. The rights will expire worthless if the Company does not consummate a Business Combination within the allotted 12-month period (or up to 18 months from the completion of the Proposed Public Offering if the Company extends the period of time to consummate a Business Combination by 2 extensions of 3 months).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The private placement units, private placement shares, private placement rights and the Class A ordinary shares underlying such rights will not be transferable, assignable or salable by the Sponsor until thirty (30) days after the completion of the Company’s initial Business Combination, except to permitted transferees. </p>
CY2023 jvsa Aggregate Purchase Price
AggregatePurchasePrice
10
CY2023 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2325000 usd
CY2024Q1 us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
187500 shares
CY2023Q4 us-gaap Loans Payable
LoansPayable
350000 usd
CY2023 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
1015000 usd
CY2023 jvsa Working Capital Loans
WorkingCapitalLoans
1150000 usd
CY2023Q4 us-gaap Preferred Stock Convertible Conversion Price
PreferredStockConvertibleConversionPrice
10
CY2023 jvsa Aggregate Amount
AggregateAmount
1150000 usd
CY2023 jvsa Compamy Extends Price Per Share
CompamyExtendsPricePerShare
0.2
CY2023Q4 jvsa Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
3 pure
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q1 us-gaap Share Price
SharePrice
10
CY2024Q1 jvsa Generating Gross Proceeds
GeneratingGrossProceeds
57500000 usd
CY2023Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
58075000 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1250000 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1250000 shares
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.06
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-18255 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-20495 usd
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2022 jvsa Accrued Offering Costs Paid Under The Promissory Noterelated Party
AccruedOfferingCostsPaidUnderThePromissoryNoterelatedParty
usd
CY2022 jvsa Deferred Offering Costs Included In The Accrued Offering Costs And Expenses
DeferredOfferingCostsIncludedInTheAccruedOfferingCostsAndExpenses
usd
CY2022 jvsa Prepaid Expense Paid By Sponsor Under The Promissory Noterelated Party
PrepaidExpensePaidBySponsorUnderThePromissoryNoterelatedParty
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001866001

Files In Submission

Name View Source Status
0001213900-24-028695-index-headers.html Edgar Link pending
0001213900-24-028695-index.html Edgar Link pending
0001213900-24-028695.txt Edgar Link pending
0001213900-24-028695-xbrl.zip Edgar Link pending
ea0201806-10k_jvspac.htm Edgar Link pending
ea020180601ex21_jvspacacq.htm Edgar Link pending
ea020180601ex31-1_jvspacacq.htm Edgar Link pending
ea020180601ex31-2_jvspacacq.htm Edgar Link pending
ea020180601ex32-1_jvspacacq.htm Edgar Link pending
ea020180601ex32-2_jvspacacq.htm Edgar Link pending
ea020180601ex4-6_jvspacacq.htm Edgar Link pending
ea020180601ex97-1_jvspacacq.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
jvsa-20231231.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
jvsa-20231231_cal.xml Edgar Link unprocessable
ea0201806-10k_jvspac_htm.xml Edgar Link completed
jvsa-20231231_def.xml Edgar Link unprocessable
jvsa-20231231_lab.xml Edgar Link unprocessable
jvsa-20231231_pre.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending